Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A0B65S3
Thu, 16.09.2021
PAION AG
PAION AG ANNOUNCES INITIATION OF PIVOTAL STUDY OF REMIMAZOLAM (BYFAVO(R)) IN PEDIATRIC PROCEDURAL SEDATION
Aachen (Germany), 16 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) announces together with Acacia Pharma (Acacia), remimazolam licensee for the U.S., the initiation of [ … ]
Thu, 02.09.2021
PAION AG
PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN
Aachen (Germany), 02 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that PAION has signed an exclusive partnership agreement with Clinigen for the supply and distribution of its products [ … ]
Wed, 01.09.2021
PAION AG
PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS
- Providing broad-spectrum coverage against bacterial pathogens
- XERAVA(R) is the third product launched by PAION in Europe
Aachen (Germany), 01 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A [ … ]
Tue, 31.08.2021
PAION AG
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO (REMIMAZOLAM) IN PROCEDURAL SEDATION IN SOUTH KOREA
- Fully-fledged entry into the endoscopy market by adding an indication for 'induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less'
- Use expanded to various surgeries, with 'Byfavo 50m [ … ]
Mon, 23.08.2021
PAION AG
PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2021
- Remimazolam partner activities: Market launches in the U.S. and South Korea, total product sales of licensees of EUR 2.7 million.
- EU market approval for remimazolam (Byfavo(R)) in procedural sedation; approval and product launch of Byfavo(R) in UK
- Expansion of European produc [ … ]
Mon, 16.08.2021
PAION AG
PAION LAUNCHES BYFAVO(R) (REMIMAZOLAM) IN THE UK FOR PROCEDURAL SEDATION
- Millions of procedures take place in the UK annually such as colonoscopies and bronchoscopies that require the use of procedural sedation
- Byfavo(R) is the first product developed by PAION approved and launched in Europe
Aachen (Germany), 16 August 2021 - The Specialty [ … ]
Fri, 16.07.2021
PAION AG
PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY
- GIAPREZA(R) is the first product launched by PAION in Europe
Aachen (Germany), 16 July 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) [ … ]
Fri, 09.07.2021
PAION AG
PAION ANNOUNCES THAT NMPA ACCEPTS SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BESYLATE IN GENERAL ANESTHESIA BY CHINESE LICENSEE YICHANG HUMANWELL
Aachen (Germany), 09 July 2021 - The specialty pharma company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that its Chinese remimazolam licensee Yic [ … ]
Tue, 29.06.2021
PAION AG
PAION RECEIVES UK MHRA APPROVAL OF BYFAVO(R) (REMIMAZOLAM) FOR PROCEDURAL SEDATION
Aachen (Germany), 29 June 2021 - The specialty pharma company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved Byfavo(R) (remimazolam besyl [ … ]
Wed, 12.05.2021
PAION AG
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021
- Remimazolam launches in the U.S. and South Korea in the first quarter of 2021
- EU market approval received for remimazolam in procedural sedation in March 2021
- Good progress in commercialization of remimazolam in the U.S., Japan, China and South Korea through our pa [ … ]